Enliven Therapeutics (ELVN) Capital Expenditures Growth (5y) (2024 - 2025)

Enliven Therapeutics (ELVN) Capital Expenditures Growth (5y) (2024 - 2025) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,801.52 Bn	66,801.23 Bn	-
2	Nanobiotix	1,935.05 Bn	1,934.98 Bn	-
3	Akari Therapeutics	1,021.31 Bn	1,021.31 Bn	-
4	BeOne Medicines	467.89 Bn	463.10 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.95 Bn	115.70 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.19 Bn	61.44 Bn	3.31 Bn
7	Belite Bio	63.46 Bn	63.46 Bn	-
8	Argenx Se	55.64 Bn	50.45 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.67 Bn	34.66 Bn	959.66 Mn
10	Enliven Therapeutics	3.43 Bn	2.98 Bn	-

Download Data